150 mg/ml (0.3%); each of saikosaponin-a, -c, -d, ginsenoside Rb1 and Rg1, 100 mg/ml (0.2%); wogonin, 20 mg/ml (0.04%); and Viscidulin III, less than 50 mg/ml (Ͻ0.1%). All other chemicals were of reagent grade and used as received.
Preparation of Liver Injury Model Rats Liver injury model rats were produced by administration of DMN to the rats after acclimatization by the following methods. DMN was injected intraperitonealy. In the case of a single administration, the dose was 40 mg/kg. For daily administration (3 d), the dose was 10 or 15 mg/kg. For administration on every other day (3 times a week for 2 weeks), the dose was 10 or 15 mg/kg. As control, normal rats were examined.
Administration of Sho-saiko-to Extract Sho-saiko-to extract was administered in pellet food by adding the extract at concentration of 1.5% (5 times of clinical dose). After preparation of liver injury model rats by administration of DMN, they were allocated to either the Sho-saiko-to extract group or the ordinary food group. The Sho-saiko-to extract group was fed with 10 g per day of Sho-saiko-to-treated food (approximately 790 mg of Sho-saiko-to/kg) for 2 weeks from the 7th day after administration of DMN. The ordinary food group was fed similarly with ordinary food.
Biochemical Examination Blood samples were collected by sacrificing rats and serum levels of AST and ALT were measured using a Vision analyzer (Dainabot, Tokyo, Japan).
Extraction and Measurement of TGF-b b in the Liver Liver TGF-b was extracted by the method described in the previous study, 3) and measured using a multiplate spectrophotometer (Ultramark, Nihon Biorad, Japan) at a wavelength of 450 nm (reference, 570 nm).
Measurement of the Hydroxyproline and Retinoid Levels in the Liver Liver retinoid levels were evaluated by measuring levels of retinol palmitate in the liver. The hydroxyproline and retinoid levels in the liver were measured by the HPLC method as described in the previous studies.
2,3)
Histopathological Examination of the Liver The area of liver fibrosis was determined according to the method of Yoshiji et al. 24) Sections of the liver excised from the rats were produced and treated by Azan-mallory staining. Azanmallory stained samples were processed by a computer using a Mac Scope, image analysis software (Mitani Shoji Inc. Japan), in 6 ocular fields (25ϫmagnification) per specimen of 6 rats.
Statistical Analysis Differences between groups were statistically examined by one-way analysis of variance. Where there was a significant difference, the means were compared by the Bonferroni method. Correlation coefficients were examined by the t-test.
RESULTS
Relationships between the Liver Inflammation or Fibrosis Parameters and DMN Administration Dose (Total Doses) in Liver Injury Rats AST, ALT, liver TGF-b, hydroxyproline levels and liver fibrosis area increased with increases in the total doses of DMN in a concentration dependent way. Liver retinoid levels decreased with increases in the total dose of DMN (Fig. 1) . The body weight of the rats administered with DMN initially decreased approximately 5% on average due to loss of appetite. However, during the 2-weeks period of the experiment, there was no noticeable difference from control in the body weight of either the group Effect of Administration of Sho-saiko-to Extract on Serum Biochemical Indicators When the rats were treated 40 mg/kg of DMN, 15 mg/kg of DMN daily for 3 d, or 10 mg/kg of DMN every other day three times a week for 2 weeks, AST levels in the Sho-saiko-to extract groups significantly decreased in a level approximately 49.8, 75.9, and 63.8% of those in the ordinary food groups. ALT levels in the Sho-saiko-to extract groups significantly decreased in a level approximately 39.5, 88.1, and 54.1% of those in the ordinary food groups. However, there were no significant differences in AST and ALT levels between the other Shosaiko-to extract groups and the ordinary food groups ( Table  1) .
The Influence of Administration of Sho-saiko-to Extract on the Liver Fibrosis Area Figure 2 shows the Azan-Mallory stained liver tissue in rats. In rats treated with 40 mg/kg of DMN, the area of blue stained collagen fibers in the Sho-saiko-to extract groups was approximately 65% smaller than in the ordinary food groups.
Effect of Administration of Sho-saiko-to Extract on TGF-b b, Liver Retinoid Levels, Hydroxyproline and Liver Fibrosis Area Levels in DMN Induced Liver-Injury Rats
When the rats were treated 40 mg/kg of DMN or 15 mg/kg of DMN daily for 3 d, TGF-b levels in the Sho-saiko-to extract groups significantly decreased in a level approximately 66.5 and 80.7% of these in the ordinary food groups. However, there were no significant differences in TGF-b levels between the Sho-saiko-to extract groups and the ordinary food groups when other regimens of DMN were used. When the rats were treated 40 mg/kg of DMN, retinoid levels in the Sho-saiko-to extract groups significantly increased to a level approximately 2.9 times higher than the ordinary food groups. However, there were no significant differences in retinoid levels between the Sho-saiko-to extract groups and the ordinary food groups when other regimens of DMN were used. When the rats were treated 40 mg/kg of DMN or 15 mg/kg of DMN daily for 3 d, hydroxyproline levels in the Sho-saiko-to extract groups significantly decreased in a level approximately 47.4 and 50.8% of the ordinary food groups. When other regimens of DMN were used, hydroxyproline levels in the Sho-saiko-to extract groups did not significantly differences from those in the ordinary food groups.
In the rats were treated 40 mg/kg of DMN or 15 mg/kg of DMN daily for 3 d, or 10 and 15 mg/kg of DMN every other day (three times a week) for 2 weeks, the liver fibrosis area in the Sho-saiko-to extract groups significantly decreased to a level approximately 64.7, 79.8, 65.8 and 62.9% of that in the ordinary food groups. However, there were no significant differences in the liver fibrosis area levels between the Shosaiko-to extract groups and the ordinary food groups when other regimens of DMN were used (Table 2) .
DISCUSSION
Sho-saiko-to, one of the most widely used Chinese herbal preparations, has long been used for the treatment of chronic liver diseases. We have already investigated its effect in retarding the process of liver fibrosis and accelerating liver regeneration, especially its effect on myofibroblasts that are thought to be deeply involved with liver fibrosis. As the results, we have found that Sho-saiko-to seems to be useful for repair of liver injury, improvement of fibrotic changes of the liver and promoting liver regeneration in liver-injured rats. This improvement seems to depend greatly on the suppression of activation of myofibroblasts in the liver, and the improvement of retinoid storage in the cells. 1) To increase the liver retinoid level and decrease the hydroxyproline level or lower collagen production, in liver-injured rats.
2) Moreover, Sho-saiko-to induces liver regeneration by increasing the production of HGF and suppressing the production of TGF-b in the liver in liver-injured rats. 3) In this time, we prepared model rats with various stages of liver injury by administering several dosages of DMN for different duration, to clarify the relationship between the stage of liver injury and effectiveness of Sho-saiko-to. We have already discussed the effects of various concentrations of extract (0.75, 1.5, 3.0%) on hepatopathy in rats in previous reports. 1, 3) According to the results of these previous experiments, we decided on the Sho-saiko-to extract concentration of 1.5%, which was administered in the present study. We have also carried out previous studies comparing the effects of Sho-saiko-to extract with glycyrrhizin, baicalin and baicalein, respectively. (Glycyrrhizin, baicalin and baicalein are the major active ingredients in Sho-saiko-to extract; especially glycyrrhizin is often administered clinically for hepatopathy.) The results of these studies showed the Sho-saiko-to extract is more effective than glycyrrhizin, baicalin and baicalein in the treatment of hepatopathy. In the DMN damage-induced rats, the liver inflammation and fibrosis parameters increased significantly and dose-dependently with the total dose of DMN compared to those in normal rats. DMN, which is a nitrosamine chemical used as an initiator of hepatopathy, is selectively and continuously accumulated in the liver. In the liver, drug metabolizing enzymes which activate the cytotoxicity of DMN and its metabolites are induced, resulting in hepatopathy. 25, 26) It was considered that the differences in the degree of liver fibrosis induced by DMN administration were resulted from different amounts of DMN and its metabolites in the liver corresponding to the amount of administrated DMN, causing different degrees of hepatopathy (AST and ALT levels). It was also considered that there was differences in the fiber expression process followed by hepatopathy, in which histological connection is repaired, (TGF-b and retinoid levels), resulting in the differences in the final amount of collagen (hydroxyproline level and area of liver fibrosis). The amount of collagen was considered to increase with increases in the amount of administered DMN, i.e., the cumulative amount of DMN, in a concentration-dependent way. Therefore, we suggested that the total dose of DMN was a useful index for predicting the severity of inflammation or fibrosis of the liver.
As for the amount of DMN administered, we also examined the effects of single administrations of 30 and 50 mg/kg (no data shown). As a result, the rats administered with a dose of 50 mg/kg all died within a week. In those administered with 30 mg/kg, AST and ALT levels were significantly higher than the control, but there were no significant differences shown by other indicators. We also examined the effects of Sho-saiko-to extract on rats whose DMN levels were over 60 mg/kg as a result of multiple administrations. In this case, we found no difference between Sho-saiko-to extract group and the ordinary food group. However, when a total dose of 40 or 45 mg/kg of DMN was used, Sho-saiko-to extract was found to improve DMN-induced liver fibrosis in rats. These findings suggested that Sho-saiko-to extract can improve DMN-induced liver fibrosis in rats when the severity of liver inflammation and fibrosis was limited within the following levels of the respective parameters: AST levels 1420 Vol. 25, No. 11 (234-264 U/l), ALT levels (208-232 U/l), TGF-b levels (1102-1265 pg/g liver tissue), hydroxyproline levels (633-719 nmol/g liver tissue), and the ratio of liver fibrosis area (9.7-10.6 times for normal rat). Moreover, Sho-saiko-to extract may not be useful for improving more advanced stage of liver inflammation and fibrosis such as cirrhosis. Therefore, it was considered that Sho-saiko-to extract should be administered to patients with mild inflammation and persistent fibrosis of the liver such as chronic hepatitis.
In the present study, we used liver retinoid levels as an index of the inhibition of myofibroblasts activation by Shosaiko-to extract. Recently, it was reported that the activated myofibroblasts released retinoid outside the cells and produced various metabolites, thus accelerating the progression of liver fibrosis. [27] [28] [29] Therefore, the relationship between retinoid levels in the liver and the inhibition of myofibroblast activation by drugs should be evaluated by considering the influence of drug administration on retinoid metabolism.
In future, we will evaluate the liver-fibrosis improving effect of Sho-saiko-to extract in more detail in comparison with clinical application of Sho-saiko-to.
